These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19625947)

  • 21. Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.
    Ibe S; Shibata N; Utsumi M; Kaneda T
    Microbiol Immunol; 2003; 47(1):71-9. PubMed ID: 12636256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-receptor switch during HAART is independent of virological success.
    Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
    J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-host evolutionary rates in HIV-1C env and gag during primary infection.
    Novitsky V; Wang R; Rossenkhan R; Moyo S; Essex M
    Infect Genet Evol; 2013 Oct; 19():361-8. PubMed ID: 23523818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
    de Oliveira T; Engelbrecht S; Janse van Rensburg E; Gordon M; Bishop K; zur Megede J; Barnett SW; Cassol S
    J Virol; 2003 Sep; 77(17):9422-30. PubMed ID: 12915557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.
    Ibáñez A; Clotet B; Martínez MA
    J Gen Virol; 2000 Jan; 81(Pt 1):85-95. PubMed ID: 10640545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of human immunodeficiency virus type 1 env and gag sequence variants derived from a mother and two vertically infected children provides evidence for the transmission of multiple sequence variants.
    Wade CM; Lobidel D; Brown AJ
    J Gen Virol; 1998 May; 79 ( Pt 5)():1055-68. PubMed ID: 9603320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C.
    Kampinga GA; Simonon A; Van de Perre P; Karita E; Msellati P; Goudsmit J
    Virology; 1997 Jan; 227(1):63-76. PubMed ID: 9007059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens.
    Ferretti F; Mackie NE; Singh GKJ; Fox J; Kaye S; McClure MO; Taylor G; Boffito M
    HIV Res Clin Pract; 2019; 20(4-5):107-110. PubMed ID: 32000615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
    Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
    Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.
    Brumme ZL; Chan KJ; Dong WW; Wynhoven B; Mo T; Hogg RS; Montaner JS; O'Shaughnessy MV; Harrigan PR
    Antivir Ther; 2003 Apr; 8(2):91-6. PubMed ID: 12741620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa.
    Neogi U; Engelbrecht S; Claassen M; Jacobs GB; van Zyl G; Preiser W; Sonnerborg A
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):80-4. PubMed ID: 26413747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women.
    Shaheen F; Sison AV; McIntosh L; Mukhtar M; Pomerantz RJ
    J Hum Virol; 1999; 2(3):154-66. PubMed ID: 10413367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of human immunodeficiency virus type 1 subtypes B and F B/F recombinant and dual infection with these subtypes in Argentina.
    Fernández-Medina D; Jansson M; Rabinovich RD; Libonatti O; Wigzell H
    Scand J Infect Dis; 1999; 31(3):235-42. PubMed ID: 10482050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
    Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
    PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
    Rossi AH; Rocco CA; Mangano A; Sen L; Aulicino PC
    AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1056-60. PubMed ID: 23458243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.